NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market Tuesday that its third-quarter revenues slipped nearly 4 percent year over year largely due to the effects of currency translation.

The Hercules, Calif.-based life science research tools firm brought in total revenues of $498.7 million for the three months ended Sept. 30, compared to $516.5 million for the third quarter of 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.